International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference

Overview

Journal J Cancer

Specialty Oncology

Date 2018 May 4

PMID 29721054

Citations 43

Authors

Naoto T Ueno

Jose Rodrigo Espinosa Fernandez

Massimo Cristofanilli

Beth Overmoyer

Dan Rea

Fedor Berdichevski

Mohamad El-Shinawi

Jennifer Bellon

Huong T Le-Petross

Anthony Lucci

Gildy Babiera

Sarah M DeSnyder

Mediget Teshome

Edward Chang

Bora Lim

Savitri Krishnamurthy

Michael C Stauder

Simrit Parmar

Mona M Mohamed

Angela Alexander

Vicente Valero

Wendy A Woodward

Affiliations

Soon will be listed here.

Abstract

National and international experts in inflammatory breast cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan Welch Inflammatory Breast Cancer Research Program at The University of Texas MD Anderson Cancer Center in Houston Texas. A consensus on the clinical management of patients with IBC was discussed, summarized, and subsequently reviewed. All participants at the conference (patients, advocates, researchers, trainees, and clinicians) were queried using the MDRing electronic survey on key management issues. A summary of the expert consensus and participant voting is presented. Bilateral breast and nodal evaluation, breast magnetic resonance imaging, positron emission tomography/computed tomography, and medical photographs were endorsed as optimal. Neoadjuvant systemic therapy, modified radical mastectomy and level I and II ipsilateral axillary node dissection, post-mastectomy radiotherapy, adjuvant targeted therapy and hormonal therapy as indicated, and delayed reconstruction were agreed-upon fundamental premises of standard non-protocol-based treatment for IBC. Consideration for local-regional therapy in de novo stage IV IBC was endorsed to provide local control whenever feasible. Variation across centers and special circumstances were discussed.

Citing Articles

Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling.

Elayoubi J, Zong Y, Schwartz E NPJ Precis Oncol. 2025; 9(1):63.

PMID: 40055517 PMC: 11889212. DOI: 10.1038/s41698-025-00845-5.

Analysis of Clinically Symptomatic Patients to Differentiate Inflammatory Breast Cancer from Mastitis in Asian Women.

Mun H, Oh H Life (Basel). 2025; 15(1).

PMID: 39859945 PMC: 11766986. DOI: 10.3390/life15010005.

Characterization of mammographic markers of inflammatory breast cancer (IBC).

Barkana B, Ahmad B, Essodegui F, Lembarki G, Pfeiffer R, Soliman A Phys Med. 2024; 129():104870.

PMID: 39657329 PMC: 11717612. DOI: 10.1016/j.ejmp.2024.104870.

Lattice radiotherapy in inflammatory breast cancer: report of a first case treated with curative aim.

Parisi S, Sciacca M, Critelli P, Ferrantelli G, Chillari F, Venuti V Radiat Oncol J. 2024; 42(2):160-165.

PMID: 38946079 PMC: 11215509. DOI: 10.3857/roj.2024.00038.

Joint EANM-SNMMI guideline on the role of 2-[F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).

Vaz S, Pilkington Woll J, Cardoso F, Groheux D, Cook G, Ulaner G Eur J Nucl Med Mol Imaging. 2024; 51(9):2706-2732.

PMID: 38740576 PMC: 11224102. DOI: 10.1007/s00259-024-06696-9.

References

Boughey J, Suman V, Mittendorf E, Ahrendt G, Wilke L, Taback B . Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013; 310(14):1455-61. PMC: 4075763. DOI: 10.1001/jama.2013.278932. View

Rea D, Francis A, Hanby A, Speirs V, Rakha E, Shaaban A . Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Cancer. 2015; 112(9):1613-5. PMC: 4453671. DOI: 10.1038/bjc.2015.115. View

Chen H, Wu K, Wang M, Wang F, Zhang M, Zhang P . A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18. Breast. 2017; 35:48-54. DOI: 10.1016/j.breast.2017.06.002. View

Le-Petross H, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson E, Harrell R . MRI features of inflammatory breast cancer. AJR Am J Roentgenol. 2011; 197(4):W769-76. DOI: 10.2214/AJR.10.6157. View

Bonev V, Evangelista M, Chen J, Su M, Lane K, Mehta R . Long-term follow-up of breast-conserving therapy in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy. Am Surg. 2014; 80(10):940-3. PMC: 4343309. View

Kerbauy L, Parmar S, Kutner J, de Gusmao B, Hamerschlak N . Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study. Sao Paulo Med J. 2016; 134(4):335-41. PMC: 10876334. DOI: 10.1590/1516-3180.2015.0223030416. View

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M . Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7):747-56. DOI: 10.1016/S1470-2045(14)70160-3. View

Carkaci S, Sherman C, Ozkan E, Adrada B, Wei W, Rohren E . (18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2013; 40(12):1809-16. DOI: 10.1007/s00259-013-2506-8. View

Scaglioni M, Arvanitakis M, Chen Y, Giovanoli P, Yang J, Chang E . Comprehensive review of vascularized lymph node transfers for lymphedema: Outcomes and complications. Microsurgery. 2016; 38(2):222-229. DOI: 10.1002/micr.30079. View

10.

Ellis G, Barlow W, Gralow J, Hortobagyi G, Russell C, Royce M . Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG.... J Clin Oncol. 2011; 29(8):1014-21. PMC: 3068051. DOI: 10.1200/JCO.2009.27.6543. View

11.

Rosso K, Tadros A, Weiss A, Warneke C, DeSnyder S, Kuerer H . Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Ann Surg Oncol. 2017; 24(10):2981-2988. DOI: 10.1245/s10434-017-5952-x. View

12.

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

13.

Niikura N, Odisio B, Tokuda Y, Symmans F, Hortobagyi G, Ueno N . Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol. 2013; 10(12):711-9. DOI: 10.1038/nrclinonc.2013.182. View

14.

Lu J, Hou J, Liu K, Parmar S, De La Fuente A, Andersson B . Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma. 2016; 57(7):1534-8. DOI: 10.3109/10428194.2015.1135434. View

15.

Ueno N, Buzdar A, Singletary S, Ames F, McNeese M, Holmes F . Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40(4):321-9. DOI: 10.1007/s002800050664. View

16.

Yamauchi H, Woodward W, Valero V, Alvarez R, Lucci A, Buchholz T . Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012; 17(7):891-9. PMC: 3399643. DOI: 10.1634/theoncologist.2012-0039. View

17.

Bristol I, Woodward W, Strom E, Cristofanilli M, Domain D, Singletary S . Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008; 72(2):474-84. PMC: 3041513. DOI: 10.1016/j.ijrobp.2008.01.039. View

18.

Dawood S, Merajver S, Viens P, Vermeulen P, Swain S, Buchholz T . International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2010; 22(3):515-523. PMC: 3105293. DOI: 10.1093/annonc/mdq345. View

19.

Iacconi C, Galman L, Zheng J, Sacchini V, Sutton E, Dershaw D . Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not?. Radiology. 2015; 279(2):378-84. PMC: 5015863. DOI: 10.1148/radiol.2015150796. View

20.

Chang E, Chang E, Soto-Miranda M, Zhang H, Nosrati N, Crosby M . Comprehensive Evaluation of Risk Factors and Management of Impending Flap Loss in 2138 Breast Free Flaps. Ann Plast Surg. 2014; 77(1):67-71. DOI: 10.1097/SAP.0000000000000263. View